[17] reported that the same GZ was useless because all the samples in GZ were proved negative for HBV, HCV, and HIV by confirmatory tests in 2020

[17] reported that the same GZ was useless because all the samples in GZ were proved negative for HBV, HCV, and HIV by confirmatory tests in 2020. kit A (0.28% reactivity and 0.43% GZ rate). HCV test kit A (0.29% reactivity and 0.57% GZ rate) was more sensitive than kit B (0.27% reactivity and 0.31% GZ rate). HIV test kit A (0.10% reactivity and 0.20% GZ rate) was more sensitive than kit B (0.08% Sitaxsentan sodium (TBC-11251) reactivity and 0.11% GZ rate). All the samples in PAK2 GZ1 were negative for NAT. HBV test kit A has negativities of 20.00% and 4.35% in GZ2 and GZ3, respectively, while HBV test kit B has negativities of 36.84% and 35.48% in GZ2 and GZ3, respectively. HCV test kit A has negativities of 100.00% and 66.67% in GZ2 and GZ3, respectively, while HCV test kit B has negativities of 72.73% and 27.78% in GZ2 and GZ3, respectively. HIV test kit A has negativities of 100.00% and 88.24% in GZ2 and GZ3, respectively, while HCV test kit B has negativities of 100.00% and 50.00% in GZ2 and GZ3, respectively. Conclusion: The GZ is useful in blood screening for HBV, HCV, and HIV. A test kit with a high sensitivity has a low specificity. Different test kits should be set with different GZs based on their sensitivity and specificity. valuevaluevalue /th th align=”center” rowspan=”1″ colspan=”1″ Significance /th /thead HBVA22 (95.65)1 (4.35)P=0.0078**B20 (64.52)11 (35.48)HCVA10 (33.33)20 (66.67)P=0.0162*B13 (72.22)5 (27.78)HIVA2 (11.76)15 (88.24)P=0.0886n.s.B3 (50.00)3 (50.00) Open in a separate window n.s.: no significance; *P 0.05; **P 0.01. Discussion Our study investigated the utility of GZ testing in the screening of HBsAg, HCV antibodies, and HIV antibodies using different CLA kits. A total of 22,081 patients requiring blood transfusions were included in this study. We found that GZ1 might be useless because all the samples with S/CO located in this interval were proved negative for all three infectious diseases by NAT. GZ2 was helpful in the screening of HBV because more than 20% of the samples with S/CO located in this interval were proved negative for HBV. GZ2 might be helpful in the screening of HCV with the use of HCV test kit B, and although the majority (72.73%) of the samples were negative, GZ2 might be useless in the screening of HIV because all the samples with S/CO located in this interval Sitaxsentan sodium (TBC-11251) were proved negative for HIV. GZ3 was useful for the screening of all three infectious diseases because only a part of the samples with S/CO located in this interval were proved negative by NAT. Archana Solanki, et al. [16] reported that a GZ ranging from 0.9 to 1 1 was useful for the screening of HBV, HCV, and HIV using ELISA in 2016, while Gunjan Bhardwaj, et al. [17] reported that the same GZ was useless because all the samples in GZ were proved negative for HBV, HCV, and HIV by confirmatory tests in 2020. Our GZ1 data agrees with Gunjan Bhardwajs study. Those contrary reports might be explained by an improvement in the testing techniques. However, this conclusion needs more careful validation with more test kits and a larger study cohort providing more blood samples. HBV can induce acute and chronic hepatitis, liver cirrhosis, and liver cancer [21-24]. The level of Sitaxsentan sodium (TBC-11251) HBsAg in the blood increases in the first few weeks after HBV infection, indicating that blood samples from people in the window period might be weakly reactive for HBsAg detection [25]. In our study, more than 50% of the Sitaxsentan sodium (TBC-11251) samples with S/CO located in GZ2 and GZ3 were positive for HBV NAT, indicating that the installation of a GZ of more than 1 could promote the screening of infectious blood samples from healthy ones, and thus improve transfusion blood safety. For the primary screening of HCV.